Savient Pharmaceuticals appoints president of Savient Europe
David Veitch takes up the role
Veitch brings extensive commercial knowledge of the European Union across marketing, sales, market access and general management to the US biopharmaceutical firm. He will be responsible for establishing, building and leading Savient's European regional organisation to launch and drive the future growth of Krystexxa (pegloticase), a drug for the treatment of chronic gout in adult patients refractory to conventional therapy.
Savient submitted its European Marketing Authorisation Application (MAA) for Krystexxa in May 2011, and anticipates EU approval in the second half of 2012.
Veitch joins Savient with more than 24 years of pharmaceutical industry experience at Bristol- Myers Squibb and SmithKline Beecham Pharmaceuticals, and has extensive knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and immunology.
Most recently he was senior vice president of European marketing and brand commercialisation at Bristol Myers Squibb.
Prior to that, Veitch spent 10 years in a number of leadership positions at Bristol-Myers Squibb.
You may also like
Regulatory
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions
Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Pharmaceutical
Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026
Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
Regulatory
FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths
The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
Regulatory
NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer
MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this perioperative setting and the first treatment advance in more than two decades
Marketing
Indena to highlight expanded HPAPI, ADC and peptide drug conjugate capabilities at DCAT Week 2026
Italian CDMO Indena will showcase its high-potency API manufacturing expertise and growing oncology-focused capabilities at DCAT Week in New York, including ten commercial HPAPIs in production and advancing work in antibody-drug and peptide drug conjugates